Your browser doesn't support javascript.
loading
Do people with hereditary cancer syndromes inform their at-risk relatives? A systematic review and meta-analysis.
Ahsan, Muhammad Danyal; Levi, Sarah R; Webster, Emily M; Bergeron, Hannah; Lin, Jenny; Narayan, Priyanka; Nelson, Becky Baltich; Li, Xuan; Fowlkes, Rana K; Brewer, Jesse T; Thomas, Charlene; Christos, Paul J; Chapman-Davis, Eloise; Cantillo, Evelyn; Holcomb, Kevin; Sharaf, Ravi N; Frey, Melissa K.
Afiliação
  • Ahsan MD; Weill Cornell Medicine, New York, NY, USA.
  • Levi SR; Weill Cornell Medicine, New York, NY, USA.
  • Webster EM; Weill Cornell Medicine, New York, NY, USA.
  • Bergeron H; Weill Cornell Medicine, New York, NY, USA.
  • Lin J; Weill Cornell Medicine, New York, NY, USA.
  • Narayan P; Weill Cornell Medicine, New York, NY, USA.
  • Nelson BB; Weill Cornell Medicine, New York, NY, USA.
  • Li X; Weill Cornell Medicine, New York, NY, USA.
  • Fowlkes RK; Weill Cornell Medicine, New York, NY, USA.
  • Brewer JT; Weill Cornell Medicine, New York, NY, USA.
  • Thomas C; Weill Cornell Medicine, New York, NY, USA.
  • Christos PJ; Weill Cornell Medicine, New York, NY, USA.
  • Chapman-Davis E; Weill Cornell Medicine, New York, NY, USA.
  • Cantillo E; Weill Cornell Medicine, New York, NY, USA.
  • Holcomb K; Weill Cornell Medicine, New York, NY, USA.
  • Sharaf RN; Weill Cornell Medicine, New York, NY, USA.
  • Frey MK; Weill Cornell Medicine, New York, NY, USA.
PEC Innov ; 2: 100138, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37214514
ABSTRACT

Purpose:

To evaluate rates of familial disclosure of hereditary cancer syndrome information.

Methods:

A systematic review and meta-analysis was conducted in accordance with PRISMA guidelines (PROSPERO no. CRD42020134276). Key electronic databases were searched to identify studies evaluating hereditary cancer syndrome cascade relative disclosure. Eligible studies were subjected to meta-analysis.

Results:

Thirty-four studies met inclusion criteria. Among 11,711 included relatives, 70% (95% CI 60 - 78%) were informed of their risk of carrying a cancer-associated pathogenic variant; of 2,875 relatives informed of their risk who were evaluated for uptake of cascade testing, 43% (95% CI 27 - 61%) completed testing. Rates of disclosure were higher among female vs male relatives (79% [95% CI 73% - 84%] vs 67% [95% CI 57% - 75%]) and first-degree vs second-degree relatives (83% [95% CI 77% - 88%] vs 58% [95% CI 45 - 69%]).

Conclusion:

Nearly one-third of at-risk relatives remain uninformed of their risk of carrying a cancer-associated pathogenic variant. Even among those informed, fewer than half subsequently complete genetic testing, representing a critical missed opportunity for precision cancer prevention. Innovation Five studies evaluating interventions to improve disclosure rates were generally ineffective. Urgent work is needed to elucidate barriers to relative disclosure by probands to develop targeted interventions that can optimize proband-mediated cascade genetic testing rates.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: PEC Innov Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: PEC Innov Ano de publicação: 2023 Tipo de documento: Article